Key result
MD+FoldX molecular modeling identifies SARS-CoV-2 antibody escape mutations with ~66% precision.
Why the study?
The ability to predict SARS-CoV-2 antibody escape mutations with computer simulations was limited by a lack of large-scale experimental data for validation.
The MD+FoldX method shows promise in predicting SARS-CoV-2 antibody escape mutations, though faster and more accurate binding affinity methods are still needed.
MD+FoldX modeling may aid escape mutation prediction; leaves open clinical translation without further validation.
Antibody escape mutations pose a significant challenge to the effectiveness of vaccines and antibody-based therapies. The ability to predict these escape mutations with computer simulations would allow us to detect threats early and develop effective countermeasures, but a lack of large-scale experimental data has hampered the validation of these calculations. In this study, we evaluate the ability of the MD+FoldX molecular modeling method to predict escape mutations by leveraging a large deep mutational scanning dataset, focusing on the SARS-CoV-2 receptor binding domain. Our results show a positive correlation between predicted and experimental data, indicating that mutations with reduced predicted binding affinity correlate moderately with higher experimental escape fractions. We also demonstrate that higher precision can be achieved using affinity cutoffs tailored to distinct SARS-CoV-2 antibodies from four different classes rather than a one-size-fits-all approach. Further, we suggest that the quartile values of optimized cutoffs reported for each class in this study can serve as a valuable guide for future work on escape mutation predictions. We find that 70% of the systems surpass the 50% precision mark, and demonstrate success in identifying mutations present in significant variants of concern and variants of interest. Despite promising results for some systems, our study highlights the challenges in comparing predicted and experimental values. It also emphasizes the need for new binding affinity methods with improved accuracy that are fast enough to estimate hundreds to thousands of antibody-antigen binding affinities.
No takes yet. Share an insight, caveat, or question.
América et al. (2024) studied SARS-CoV-2 (n=4,443). MD+FoldX molecular modeling method vs. Experimental deep mutational scanning (DMS) data was evaluated on Correlation between predicted binding affinity and experimental escape fraction, and precision of escape mutation identification (mean Pearson correlation 0.52). The MD+FoldX molecular modeling method demonstrated a mean Pearson correlation of 0.52 with experimental escape fractions and achieved 66% precision in identifying SARS-CoV-2 antibody escape mutations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: